

Rabbit Anti-CDKN2A/p16-INK4a/PE Conjugated antibody

SL0740R-PE

Product Name	Anti-CDKN2A/p16-INK4a/PE
Chinese Name	PE 标记的抑癌基因 p16 抗体
Alias	cyclin-dependent kinase inhibitor 2A; CDK4I; p16-INK4; p16-INK4a; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A, isoform 1; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cell cycle inhibitor; cyclin-dependent kinase inhibitor 2a p16Ink4a; cell cycle regulator; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 2; Cdkn2a; Arf; INK4A; MTS1; p16; p16Cdkn2a; p19ARF; CD2A1_HUMAN.
Research Area	Tumour Cell biology immunology Signal transduction Apoptosis Cyclin
Immunogen Species	Rabbit
Clonality	Polyclonal
React Species	Human
Applications	Flow-Cyt=1:50-200 IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
Molecular weight	17kDa
Form	Lyophilized or Liquid
Concentration	1mg/ml
immunogen	KLH conjugated synthetic peptide derived from human P16
Lsotype	IgG
Purification	affinity purified by Protein A
Storage Buffer	1M TBS(pH7.4) with 1% BSA, 3% Proclin300 and 50% Glycerol.
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 1M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Product Detail	background:

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012].

Function:

Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.

Subunit:

Heterodimer with CDK4 or CDK6. Predominant p16 complexes contained CDK6. Interacts (isoforms 1,2 and 4) with CDK4 (both 'T-172'-phosphorylated and non-phosphorylated forms); the interaction inhibits cyclin D-CDK4 kinase activity. Interacts with ISCO2.

Subcellular Location:

Cytoplasm. Nucleus.

Tissue Specificity:

Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.

DISEASE:

Note=The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients.

Defects in CDKN2A are the cause of cutaneous malignant melanoma type 2 (CMM2) [MIM:155601]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.

Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719]. Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. [DISEASE] Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome (MASTS) [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.

Similarity:

Belongs to the CDKN2 cyclin-dependent kinase inhibitor family. Contains 4 ANK repeats.

Database links:

[Entrez Gene: 1029](#) Human

[Entrez Gene: 12578](#) Mouse

[Entrez Gene: 25163](#) Rat

[Omim: 600160](#) Human

[SwissProt: P42771](#) Human

[SwissProt: P51480](#) Mouse

[SwissProt: Q9R0Z3](#) Rat

[Unigene: 512599](#) Human

[Unigene: 4733](#) Mouse

[Unigene: 48717](#) Rat

Important Note:

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

细胞周期失控是癌变的重要原因。p16 是近年来发现的第一个直接参与细胞周期调控的抑癌基因，其表达产物为 p16 蛋白。

p16 基因是一种重要的抑癌基因，在正常细胞中起负反馈作用，当 p16

基因突变或丢失时，细胞增殖失去控制使细胞无限制地增殖。

p16 主要功能是通过抑制 CDK4 而阻止细胞由 G1 期进入 S 期，使细胞增殖受到限制。用于各种恶性 Tumour 如肺癌、恶黑、乳腺癌的研究。目前的研究细胞周期依赖激酶抑制 p16INK4a 蛋白在宫颈上皮内病变 (CIN)中作为一个新标记物。

p16INK4a 的过表达与 HPV E7 区(病毒早期蛋白即病毒致癌基因编码区)活性有密切相关性。

p16/CDKN2 基因是新近发现的 Tumour 抑制基因，已有研究表明该基因在许多 Tumour 出现缺失、突变或重排现象。